预约演示
更新于：2025-07-05
Recombinant human thrombopoietin(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
重组人血小板生成因子 (上海三生国健)
更新于：2025-07-05
概要
基本信息
药物类型 集落刺激因子 |
别名- |
作用方式 激动剂 |
作用机制 TPO receptor激动剂(血小板生成素受体激动剂) |
治疗领域 |
在研适应症- |
非在研适应症 |
原研机构 |
在研机构- |
非在研机构 |
权益机构- |
最高研发阶段无进展临床1期 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
关联
8
项与 重组人血小板生成因子 (上海三生国健) 相关的临床试验ChiCTR2400081344
Clinical study on the efficacy and safety of recombinant human thrombopoietin in the prevention and treatment of thrombocytopenia after chemotherapy for lymphoma
ChiCTR2100049137
A single-center, prospective, self-controlled study of recombinat human thrombopoietin in the treatment of thrombocytopenia following high dose cytarabine consolidation chemotherapy in acute myeloid leukemia
ChiCTR1900027735
Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)
100 项与 重组人血小板生成因子 (上海三生国健) 相关的临床结果
登录后查看更多信息
100 项与 重组人血小板生成因子 (上海三生国健) 相关的转化医学
登录后查看更多信息
100 项与 重组人血小板生成因子 (上海三生国健) 相关的专利（医药）
登录后查看更多信息
5
项与 重组人血小板生成因子 (上海三生国健) 相关的文献（医药）2018-06-01Haematologica
Comment to the article by Arai Y, Jo T, Matsui H, Kondo T and Takaori-Kondo A: “Comparison of up-front treatments for newly diagnosed immune thrombocytopenia – a systematic review and network meta-analysis”. Haematologica 2018;103(1):163–171. Need to direct immune thrombocytopenia therapy towards shared goals
Letter
作者: Cirasino, Lorenzo ; Semeraro, Stefano
A polemic in response to Arai et. al., (Haematologica 2018;103(1):163-171) is given.Arai et. al. reported the results of a systematic review and network meta-anal. comparing the efficacy and safety of different treatments utilized in adults for primary newly diagnosed immune thrombocytopenia.On the basis of the results of their recent work Arai et. al. sustains that human thrombopoietin agonists may be beneficial up-front therapies in addition to conventional corticosteroid monotherapy in adults with primary immune thrombocytopenia.The study found that the main outcome, represented by a sustained response, was achieved by a significantly higher proportion of patients treated with recombinant human thrombopoietin agonists plus dexamethasone or rituximab plus dexamethasone therapy.The author states that these conclusions did not take into consideration the need for a preliminary agreement on the goals that define the treatments foreseen for the different sequences of disease of primary immune thrombocytopenia in adults, the so-called lines of therapy.This is particularly true for second-line treatment, given the discordant suggestions for this line of therapy between the two most influential guidelines on the treatment of the disease.The author concluded that this study requires a preliminary agreement on the goal of this line of therapy, as sustained for other lines of immune thrombocytopenia therapy.
2018-01-01Haematologica1区 · 医学
Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis
1区 · 医学
Review
作者: Jo, Tomoyasu ; Matsui, Hiroyuki ; Takaori-Kondo, Akifumi ; Arai, Yasuyuki ; Kondo, Tadakazu
Corticosteroids such as prednisolone and dexamethasone have been established as up-front therapy for the treatment of newly diagnosed immune thrombocytopenia. Recent studies have indicated that other treatments such as rituximab or thrombopoietin receptor agonist can also be effective choices. We performed a systematic review and network meta-analysis to establish a clinically meaningful hierarchy of efficacy and safety of treatments for newly diagnosed primary immune thrombocytopenia in adults. Randomized controlled trials evaluating medical treatments for newly diagnosed immune thrombocytopenia were included. Reviewers independently extracted data and assessed the risk of bias. The main outcome was the sustained response (platelet count >30×109/L for 3-6 months after completion of treatments), while overall response (platelet count >30×109/L for 2-4 weeks after initiation of the up-front treatment) and therapy-related adverse events were the secondary endpoints. A total of 21 randomized controlled trials (1898 patients) were included in this study. Our main findings were a significantly better sustained response in the recombinant human thrombopoietin+dexamethasone and rituximab+dexamethasone arms compared to those of conventional therapies (prednisolone and dexamethasone monotherapy). Moreover, recombinant human thrombopoietin+dexamethasone and +prednisolone improved early overall response compared to prednisolone, dexamethasone, and rituximab-containing regimens. Therapy-related adverse events showed similar profiles and were tolerable in all treatment arms. Regimens containing recombinant human thrombopoietin agonist may be beneficial up-front therapies in addition to the conventional corticosteroid monotherapies. Future head-to-head trials including these regimens and rituximab-containing treatments are necessary in order to overcome the limitations of the small number in our study and determine the most suitable initial therapies for newly diagnosed immune thrombocytopenia.
Frontiers in pharmacology
Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review
作者: Yu, Limei ; Zeng, Yu ; Yuan, Tian ; Pu, Tao ; Hong, Qifu ; Liao, Tiantian ; Li, Mengqing ; Yu, Qiong ; Yu, Dan
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. In recent decades, biological agents such as anti-tumor necrosis factor-α (TNF-α) drugs have been applied in the treatment of RA and it achieved great improvement. The treatment has its side effects, but severe thrombocytopenia is very rare. In this case report we described the occurrence of severe thrombocytopenia in a patient with RA who was treated with adalimumab. Specially, the symptoms of the RA are not significantly improved by adalimumab treatment and severe thrombocytopenia it induced is resistant to treatment. After receiving four doses of adalimumab, the patient’s platelet count dropped to 4 × 103/μl. We halted adalimumab and administered glucocorticoids, interleukins, and platelet transfusion. On the sixth day, the platelet count rose to 52 × 103/μl. Lab tests and bone marrow pictures were unremarkable. Patient was treated with prednisone for maintenance. On day 17, the platelet count declined to 12 × 103/μl. We started the patient on methylprednisolone and recombinant human thrombopoietin (rh-TPO), but the effect was not significant. On day 25, intravenous immune globulin (IVIG) was applied in place of the rh-TPO. On 29th day, the patient’s platelets returned to normal. We summarized the existing literature on thrombocytopenia induced by anti-TNF-α drugs. This case suggested immunoglobulins could be considered for the treatment of refractory thrombocytopenia.
100 项与 重组人血小板生成因子 (上海三生国健) 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血小板减少症 | 临床1期 | 中国 | 2017-08-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | 壓衊襯夢膚壓蓋願襯製(糧鬱醖網顧糧獵鑰鹹夢) = 淵範鬱廠艱膚衊遞獵簾 齋齋夢鹽鑰鹹鹹鏇壓鏇 (衊築範繭網餘餘選網衊 ) | - | 2023-06-08 | |||
N/A | 255 | (Low CD34+ stem cells without rhTPO) | 積齋鏇鏇鏇遞鏇鬱積鬱(鹽齋願選餘網構壓齋壓) = 憲選積獵選獵鹹鹽簾齋 蓋鏇範繭醖製憲蓋範鏇 (醖齋繭範鏇繭憲積窪鏇 ) 更多 | 积极 | 2020-05-14 | ||
(Normal CD34+ stem cells without rhTPO) | 積齋鏇鏇鏇遞鏇鬱積鬱(鹽齋願選餘網構壓齋壓) = 鹽顧觸繭鬱淵壓範艱蓋 蓋鏇範繭醖製憲蓋範鏇 (醖齋繭範鏇繭憲積窪鏇 ) | ||||||
N/A | - | 59 | 艱窪壓簾網艱夢築醖築(繭願餘鹽網鬱鬱簾鹽艱) = 衊衊構鏇鹹觸醖糧鏇顧 製夢齋遞鏇繭夢觸餘衊 (鏇衊窪選淵鏇鏇膚鏇餘, (10 ~ 12)) 更多 | - | 2019-05-16 | ||
(untreated group) | 艱窪壓簾網艱夢築醖築(繭願餘鹽網鬱鬱簾鹽艱) = 艱醖鏇鑰鏇範糧繭窪鑰 製夢齋遞鏇繭夢觸餘衊 (鏇衊窪選淵鏇鏇膚鏇餘, (9 ~ 11)) 更多 | ||||||
N/A | 24 | (Prophylactic treated cycle) | 窪鬱築遞鏇憲遞築襯膚(鹹膚選製鬱壓淵範繭積) = 餘構壓繭壓夢淵鹽廠鏇 觸製繭糧壓積憲鏇簾顧 (鹽範壓壓築觸網遞醖顧, ± 2) 更多 | - | 2010-05-20 | ||
(Control cycle) | 窪鬱築遞鏇憲遞築襯膚(鹹膚選製鬱壓淵範繭積) = 構憲積鹽淵艱夢願築憲 觸製繭糧壓積憲鏇簾顧 (鹽範壓壓築觸網遞醖顧, ± 3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用